Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Purchased by Royal London Asset Management Ltd.

Royal London Asset Management Ltd. boosted its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBHFree Report) by 3.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 82,959 shares of the medical equipment provider’s stock after purchasing an additional 2,915 shares during the period. Royal London Asset Management Ltd.’s holdings in Zimmer Biomet were worth $10,096,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in ZBH. Norges Bank bought a new position in shares of Zimmer Biomet in the fourth quarter valued at $266,896,000. American Century Companies Inc. raised its stake in Zimmer Biomet by 21.2% during the 3rd quarter. American Century Companies Inc. now owns 4,863,741 shares of the medical equipment provider’s stock valued at $545,809,000 after purchasing an additional 852,186 shares during the period. Van ECK Associates Corp raised its stake in Zimmer Biomet by 23.7% during the 4th quarter. Van ECK Associates Corp now owns 2,838,558 shares of the medical equipment provider’s stock valued at $345,452,000 after purchasing an additional 543,344 shares during the period. Qube Research & Technologies Ltd acquired a new stake in Zimmer Biomet during the 3rd quarter valued at $57,972,000. Finally, Primecap Management Co. CA raised its stake in Zimmer Biomet by 10.5% during the 4th quarter. Primecap Management Co. CA now owns 5,086,578 shares of the medical equipment provider’s stock valued at $619,037,000 after purchasing an additional 484,151 shares during the period. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have issued reports on ZBH shares. StockNews.com downgraded shares of Zimmer Biomet from a “strong-buy” rating to a “buy” rating in a research note on Monday, February 19th. Canaccord Genuity Group reaffirmed a “hold” rating and issued a $130.00 price target on shares of Zimmer Biomet in a research note on Friday, February 23rd. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $140.00 price target on shares of Zimmer Biomet in a research note on Friday, February 9th. The Goldman Sachs Group assumed coverage on shares of Zimmer Biomet in a research note on Thursday, May 30th. They issued a “neutral” rating and a $129.00 price target on the stock. Finally, Barclays dropped their price target on shares of Zimmer Biomet from $130.00 to $125.00 and set an “underweight” rating on the stock in a research note on Friday, May 31st. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, Zimmer Biomet presently has a consensus rating of “Hold” and an average target price of $133.75.

View Our Latest Research Report on ZBH

Zimmer Biomet Trading Down 0.0 %

Shares of NYSE:ZBH opened at $113.33 on Friday. The company has a market cap of $23.32 billion, a P/E ratio of 24.53, a P/E/G ratio of 2.04 and a beta of 1.02. The stock’s 50-day moving average is $120.60 and its 200-day moving average is $121.94. Zimmer Biomet Holdings, Inc. has a 52-week low of $102.00 and a 52-week high of $147.50. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.80 and a current ratio of 1.66.

Zimmer Biomet (NYSE:ZBHGet Free Report) last issued its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported $1.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.87 by $0.07. The company had revenue of $1.89 billion for the quarter, compared to the consensus estimate of $1.87 billion. Zimmer Biomet had a return on equity of 12.70% and a net margin of 12.93%. The firm’s revenue was up 3.2% compared to the same quarter last year. During the same period last year, the business posted $1.89 earnings per share. Equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.1 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, July 31st. Stockholders of record on Wednesday, June 26th will be given a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.85%. The ex-dividend date is Wednesday, June 26th. Zimmer Biomet’s dividend payout ratio is currently 20.78%.

Zimmer Biomet Company Profile

(Free Report)

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

Featured Stories

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.